Human BioSystems
Human BioSystems: Human BioSystems to Receive Its 4th U.S. Patent: “Preservation of Blood Platelets with Citrate”
Corporate-news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Human BioSystems to Receive Its 4th U.S. Patent: “Preservation of Blood
Platelets with Citrate”
Palo Alto, CA – May 16, 2006 – (OTCBB:HBSC) – On the heels of its earlier
announcement regarding the receipt of a third patent (U.S. Patent
#7,029,839: “Methods & Solutions for Storing Donor Organs”), Human
BioSystems announced today that it has been notified by the U.S. Patent
Office that it will receive an additional patent titled “Preservation of
Blood Platelets with Citrate”. This patent grant further adds to the
Company’s increasing technology base covering a variety of cell
preservation methods.
The two major recipient groups for blood platelets are cancer patients that
have undergone chemotherapy and/or radiation treatment (about 70%), and
trauma patients suffering from extensive bleeding.
“This new patent covers the process of cooling blood platelets to near zero
degrees Centigrade to keep them fresh and preserved for greater than the
current standard of 5 days. We anticipate being able to extend this process
to 7 days and beyond. This will reduce the current need to discard stored
platelets that have been preserved by existing methods,” explained Dr.
David Winter, President of Human BioSystems.
Current technology provides for the storage of platelets at room
temperature. This allows any bacteria present to grow rapidly over the
current 5-day allowable shelf period.
“By developing a cooling method that prolongs the preservation of
platelets, we greatly reduce the risk of bacterial infection while
increasing the availability of essential medical resources required to
treat cancer and trauma patients,” Dr. Winter stated.
Human BioSystems is a developer of preservation platforms for organs and
other biomaterials. The Company, which is headquartered in Palo Alto,
California with research facilities in Michigan, has made tremendous
progress in its nine-year history. This fourth patent is another milestone
for Human BioSystems. The Company is also currently conducting tests with
two independent and FDA approved laboratories on its proprietary
preservation methods.
Contact:
Human BioSystems Investor Relations Investor Relations
Harry Masuda Yes International Concept Communications
CEO Rich Kaiser James D. Caldwell
(650) 323-0943 (800) 631-8127 (727) 447-0514
hmasuda@humanbiosystems.com rich@yesinternational.com jca@concetcg.com
(c)DGAP 18.05.2006
—————————————————————————
Language: English
Issuer: Human BioSystems
1127 Harker Avenue
CA 94301, Palo Alto Vereinigte Staaten von Amerika
Phone: 001-650-323-0943
Fax: 001-650-327-8658
email: info@humanbiosystems.com
WWW: www.humanbiosystems.com
ISIN: US44485X1090
WKN: 157049
indices:
End of News DGAP News-Service
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found